CytomX Therapeutics Files 2024 10-K
Ticker: CTMX · Form: 10-K · Filed: Mar 6, 2025 · CIK: 1501989
| Field | Detail |
|---|---|
| Company | Cytomx Therapeutics, INC. (CTMX) |
| Form Type | 10-K |
| Filed Date | Mar 6, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, pharmaceuticals, collaboration, financials
TL;DR
CytomX filed its 2024 10-K. Check financials and partnerships with BMS & AbbVie.
AI Summary
CytomX Therapeutics, Inc. filed its 2024 10-K on March 6, 2025, reporting on its fiscal year ending December 31, 2024. The company is involved in pharmaceutical preparations and has ongoing collaborations with major entities like Bristol Myers Squibb Company and AbbVie Ireland Unlimited Company. Key financial and operational details for the fiscal year 2024 are presented in this filing.
Why It Matters
This filing provides a comprehensive overview of CytomX Therapeutics' financial health, strategic partnerships, and operational performance for the past fiscal year, crucial for investors and stakeholders to assess the company's trajectory.
Risk Assessment
Risk Level: medium — The company operates in the highly competitive and regulated pharmaceutical industry, with significant reliance on collaborations and clinical trial success.
Key Numbers
- 2834 — SIC Code (Indicates the company operates in Pharmaceutical Preparations)
- DE — State of Incorporation (Company incorporated in Delaware)
Key Players & Entities
- CytomX Therapeutics, Inc. (company) — Filer
- Bristol Myers Squibb Company (company) — Collaborative arrangement partner
- AbbVie Ireland Unlimited Company (company) — Collaborative arrangement partner
- Astellas Pharma Inc. (company) — Collaborative arrangement partner
- ImmunoGen Inc. (company) — Collaborative arrangement partner
- University of California Santa Barbara (company) — Research partner
- 2024-12-31 (date) — Fiscal year end
- 2025-03-06 (date) — Filing date
FAQ
What were the key financial highlights for CytomX Therapeutics in the fiscal year ending December 31, 2024?
The 10-K filing for the fiscal year ending December 31, 2024, provides detailed financial statements, including revenue, expenses, and net income/loss, which are crucial for understanding the company's financial performance.
What are the significant collaborations CytomX Therapeutics has in place?
CytomX Therapeutics has ongoing collaborative arrangements with entities such as Bristol Myers Squibb Company, AbbVie Ireland Unlimited Company, and Astellas Pharma Inc., as detailed in the filing.
When was the 10-K filing submitted to the SEC?
The 10-K filing for CytomX Therapeutics was filed with the SEC on March 6, 2025.
What is the primary business of CytomX Therapeutics?
CytomX Therapeutics, Inc. is classified under the Standard Industrial Classification code 2834, indicating its primary business is in Pharmaceutical Preparations.
Are there any specific agreements or arrangements mentioned regarding clinical development milestones?
Yes, the filing references 'ClinicalDevelopmentMilestones' in the context of collaborations, suggesting performance-based payments or agreements related to the advancement of drug candidates.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 6, 2025 regarding CytomX Therapeutics, Inc. (CTMX).